Kaspofungin Teva (Caspofungin)

Caspofungin belongs to the echinocandin class and inhibits the enzyme β‑(1,3)‑D‑glucan synthase. By blocking the synthesis of β‑(1,3)‑D‑glucan, an essential component of the fungal cell wall, the drug weakens the wall and leads to fungal cell lysis while sparing human cells.

The dosing regimen for Kaspofungin Teva is determined by the prescribing clinician based on the specific infection, patient weight, renal and hepatic function, and other clinical factors. The prescriber will set the appropriate dose and infusion schedule.

Safety data for caspofungin in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by the treating physician.

To order Kaspofungin Teva, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required), and import documentation.

Caspofungin is an echinocandin, offering a mechanism distinct from azole antifungals such as fluconazole. Compared with azoles, caspofungin has a lower risk of drug‑drug interactions and is effective against many azole‑resistant Candida species, but it requires intravenous administration and may be more costly.

Kaspofungin Teva must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. Once prepared for infusion, it should be used within the time frame specified in the product labeling.

Kaspofungin Teva is administered as an intravenous infusion. The solution is reconstituted according to the manufacturer’s instructions and infused over a period typically ranging from 1 to 2 hours, depending on the clinical protocol and patient tolerance.

Serious risks include severe hypersensitivity reactions such as anaphylaxis, hepatic failure indicated by marked liver enzyme elevation or jaundice, and acute renal impairment. Patients should be monitored closely for signs of these events, and treatment should be discontinued if they occur.

Kaspofungin Teva is contraindicated in individuals with known hypersensitivity to caspofungin or any component of the formulation. Caution is also advised for patients with severe hepatic impairment, as the drug may accumulate and increase toxicity risk.